Saturday, December 21, 2024
12/21/2024
PROJECT SUMMARY Mitochondrial diseases (MD) are a clinically heterogeneous group of disorders caused by respiratory chain dysfunction and metabolic failure. These diseases often result from pathogenic mutations in genes that function in oxidative phosphorylation or mitochondrial DNA (mtDNA) maintenance, are often debilitating, and have limited treatment options with no cures. Environmental exposures, such as microbial infection, appear to exacerbate the stepwise progression of MD. MD patients are also more susceptible to recurrent infections from opportunistic respiratory pathogens including Pseudomonas aeruginosa (PA). Infections can quickly spiral out of control, leading to sepsis and unrestrained inflammatory responses in MD patients. The underlying immune alterations in MD that enhance immunopathology are unclear, constituting a key gap in knowledge that complicates treatment and increases mortality in these patients. Thus, there is a critical need for mechanistic research to advance immune-focused therapies for MD. Mutations in mtDNA polymerase gamma (PolG) represent the most prevalent single-gene cause of MD. Ongoing experiments using a faithful mouse model of PolG-related MD have uncovered novel immune alterations in PolG mutant animals. Notably, PolG mutants exhibit elevated numbers of myeloid immune cells in the lung and increased lung neutrophil infiltration and cytokine production after instillation of bacterial lipopolysaccharide or intranasal delivery of PA. Additional preliminary experiments revealed that PolG mutant macrophages undergo increased pyroptosis after exposure to PA, which is driven by elevated expression and activity of caspase-11. Prior mechanistic studies showed widespread repression of the transcription factor nuclear erythroid 2-related factor 2 (Nrf2) in PolG mutant mice. Nrf2 orchestrates both antioxidant and anti-inflammatory responses. Stabilizing Nrf2 with the FDA-approved drug dimethyl fumarate (DMF) was effective at reducing inflammation in PolG macrophages exposed to live PA. Therefore, this proposal will test the central hypothesis that loss of Nrf2 activity promotes myeloid cell hyperinflammation, lung immunopathology, and increased morbidity and mortality in PolG mutant mice and patients with PolG-related MD. Specific Aim 1 will test the hypothesis that elevated type I interferon (IFN-I) signaling and the subsequent reduction of Nrf2 activity in PolG mutant macrophages promotes hyperinflammatory innate immune signaling and inflammatory cell death via potentiated non-canonical inflammasome activation. Specific Aim 2 tests the hypothesis that hyperinflammatory innate immune responses contribute to acute lung injury during PA infection using a faithful in vivo model of PolG-related MD. Both Aims will incorporate in vitro and in vivo DMF treatments to characterize how Nrf2 stabilization alleviates hyperinflammation and reduces lung pathology during PA infection. This research will fundamentally advance understanding of innate immune defects in a relevant model of MD. It may also lead to the development of innovative Nrf2-based therapies to slow the damaging toll of respiratory infections and lung immunopathology in PolG-related MD or other mitochondrial disorders.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).